Barrett's esophagus surgery: Difference between revisions
Jump to navigation
Jump to search
Amresh Kumar (talk | contribs) |
Amresh Kumar (talk | contribs) |
||
| Line 7: | Line 7: | ||
==Surgery== | ==Surgery== | ||
According to the American College of Gastroenterology, | According to the American College of Gastroenterology, indication for the [[surgery]] in [[Barrett's esophagus]] [[patients]] are:<ref name="urlDiagnosis and Management of Barrett’s Esophagus | American College of Gastroenterology">{{cite web |url=https://gi.org/guideline/diagnosis-and-management-of-barretts-esophagus/ |title=Diagnosis and Management of Barrett’s Esophagus | American College of Gastroenterology |format= |work= |accessdate=}}</ref><ref name="pmid22798736">{{cite journal |vauthors=Amano Y, Kinoshita Y |title=Barrett esophagus: perspectives on its diagnosis and management in asian populations |journal=Gastroenterol Hepatol (N Y) |volume=4 |issue=1 |pages=45–53 |year=2008 |pmid=22798736 |pmc=3394474 |doi= |url=}}</ref> | ||
* | *Antireflux [[surgery]] should not be pursued in [[patients]] with BE as an [[antineoplastic]] measure. However, this [[surgery]] should be considered in those with incomplete control of [[reflux]] on optimized [[medical]] [[therapy]]. | ||
*In cases of [[Endoscopic]] [[adenocarcinoma]] (EAC) with [[invasion]] into the [[submucosa]], especially those with [[invasion]] to the mid or deep [[submucosa]] (T1b, sm2–3), [[esophagectomy]], with | *In cases of [[Endoscopic]] [[adenocarcinoma]] (EAC) with [[invasion]] into the [[submucosa]], especially those with [[invasion]] to the mid or deep [[submucosa]] (T1b, sm2–3), [[esophagectomy]], with consideration of [[neoadjuvant]] [[therapy]], is recommended in the [[surgical]] candidate. | ||
*In patients with T1a or T1b sm1 EAC, poor [[differentiation]], | *In patients with T1a or T1b sm1 EAC, poor [[differentiation]], lymphovascular [[invasion]], or incomplete [[Endoscopic]] [[mucosal]] [[resection]] (EMR ) should prompt consideration of [[surgical]] and/or multimodality therapies. | ||
Various [[surgical]] | Various [[surgical]] methods used for the treatment of [[Barrett's esophagus]] are: | ||
*[[Esophagectomy]] | *[[Esophagectomy]] | ||
*[[Nissen fundoplication]] is used in the patient with [[GERD]] [[symptoms]]. | *[[Nissen fundoplication]] is used in the patient with [[GERD]] [[symptoms]]. | ||
Revision as of 15:14, 6 February 2018
|
Barrett's Esophagus Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Barrett's esophagus surgery On the Web |
|
American Roentgen Ray Society Images of Barrett's esophagus surgery |
|
Risk calculators and risk factors for Barrett's esophagus surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2]
Overview
Surgery
According to the American College of Gastroenterology, indication for the surgery in Barrett's esophagus patients are:[1][2]
- Antireflux surgery should not be pursued in patients with BE as an antineoplastic measure. However, this surgery should be considered in those with incomplete control of reflux on optimized medical therapy.
- In cases of Endoscopic adenocarcinoma (EAC) with invasion into the submucosa, especially those with invasion to the mid or deep submucosa (T1b, sm2–3), esophagectomy, with consideration of neoadjuvant therapy, is recommended in the surgical candidate.
- In patients with T1a or T1b sm1 EAC, poor differentiation, lymphovascular invasion, or incomplete Endoscopic mucosal resection (EMR ) should prompt consideration of surgical and/or multimodality therapies.
Various surgical methods used for the treatment of Barrett's esophagus are:
- Esophagectomy
- Nissen fundoplication is used in the patient with GERD symptoms.
References
- ↑ "Diagnosis and Management of Barrett's Esophagus | American College of Gastroenterology".
- ↑ Amano Y, Kinoshita Y (2008). "Barrett esophagus: perspectives on its diagnosis and management in asian populations". Gastroenterol Hepatol (N Y). 4 (1): 45–53. PMC 3394474. PMID 22798736.